

For more information on any of the following trials, please contact:
Salitah Qureshi, (212) 305-1682

PRISM-SCARLET (Johnson & Johnson)

PTG-200 (IL-23)

IP administration: Oral

PI: Garrett Lawlor

Disease: mild/moderate Crohn's Disease

Inclusion criteria: endoscopically and clinically active CD, failed biologics, corticosteroids, immunomodulators.

Status: Enrolling

M16-067 (AbbVie)

Risankizumab (IL-23)

IP administration: IV and Subcutaneous injection

PI: Garrett Lawlor

Disease: moderate/severe ulcerative colitis

Inclusion criteria: endoscopically and clinically moderate/severely active UC. Must have failed a biologic

Exclusion criteria: previous Stelara use

Status: Enrolling

ADMIRE CD-II (Tigenix)

Cx601 (adult allogenic expanded adipose derived Stem Cells)

IP administration: injection under anesthesia

PI: Garrett Lawlor

Disease: Complex Fistula(s) due to Crohn's Disease

Inclusion criteria: Complex perianal fistula(s); clinically controlled nonactive/ mildly active Crohn's Disease; failed treatment of fistula with immunosuppressant or biologics

Exclusion Criteria: actively draining Simple subcutaneous fistula

Status: Enrolling

M20-259 (AbbVie)

Risankizumab vs Ustekinumab

IP administration: IV and Subcutaneous injection

PI: Garrett Lawlor

Disease: moderate/severe Crohn's Disease

Inclusion criteria: endoscopically and clinically active CD, anti-TNF therapy

Exclusion criteria: previous Stelara, natalizumab, vedolizumba and risankizumab use

Status: Enrolling

PRECIOUS

Predicting Crohn's and Colitis Outcomes in the US

PI: Garrett Lawlor

Disease: Crohn's Disease or Ulcerative Colitis

Inclusion criteria: Active ulcerative colitis/Crohn's Disease; not currently receiving systemic therapy with steroids, immunomodulators or biologics

Exclusion criteria: receive biologics as a first line therapy

Status: Enrolling

SAPPHIRE

Safety of Immunosuppression in a Prospective Cohort of IBD with a History of Cancer

PI: Garrett Lawlor

Disease: Ulcerative colitis or Crohn's Disease

Inclusion criteria: 1st cancer diagnosis within the last 5 years

Exclusion criteria: chemotherapy/ radiation treatment at enrollment

Status: Enrolling

UPCOMING TRIALS

IM011023 (Bristol Meyer Squibb)

BMS-986165 (Tyrosine Kinase 2 inhibitor)

IP administration: Oral

PI: Garrett Lawlor

Disease: moderate/ severe Crohn's Disease

Inclusion criteria: endoscopically and clinically active CD; failed any medication.

Exclusion criteria: previous Stelara use

TAK-018 (Takeda)

TAK-018

IP administration: Oral

PI: Bo Shen

Disease: Prevention of postoperative Crohn's Disease recurrence

Inclusion criteria: planned laparoscopic ileocecal resection with primary anastomosis; postop discontinuation of all medication for CD treatment

Exclusion criteria: More than 3 previous CD surgical procedures; small bowel resection that exceeds 100 cm

KFAH (Eli Lilly)

LY3471851 (IL-2)

IP Administration: Subcutaneous injection

PI: Garrett Lawlor

Disease: Moderate/ Severe Ulcerative Colitis

Inclusion criteria: failed corticosteroids, immunomodulators; bio-naïve

LUCENT (Eli Lilly)

Mirikizumab (IL-23) vs. Vedolizumab

IP administration: IV and Subcutaneous injection

PI: Garrett Lawlor

Disease: Moderate/ Severe Ulcerative Colitis

Inclusion criteria: failed any medication

Exclusion criteria: previous vedolizumab, stelara use